• Home
  • About GPCRCentral

GPCR News

Entries RSS | Comments RSS
  • Tags

    5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
  •  

    August 2008
    M T W T F S S
    « Jul   Sep »
     123
    45678910
    11121314151617
    18192021222324
    25262728293031

University of Texas publsihes series for Cannabinoid CB2 agonists

Posted on August 1, 2008 by crimsoncanary

Researchers at he University of Texas have published a series of cannabinoid receptor 2 (CB2) agonists for the treatment of neuropathic pain.

Filed under: gpcr | Tagged: agonist, Cannabinoid, Cannabinoid CB2, CB2, Preclinical, Research, Univ Texas

« Evotec/Pfizer initiate Phase I trial of VR1 antagonist EPIX initiate Phase IIb trial of 5HT2b antagonist PRX-08066 in COPD »

Leave a Reply

Click here to cancel reply.

  • Calendar

    • August 2008
      M T W T F S S
      « Jul   Sep »
       123
      45678910
      11121314151617
      18192021222324
      25262728293031
  • Blogroll

    • CrimsonCanary.com
    • GPCRCentral.com
    • IonChannelCentral.com
    • Kinasecentral.com
    • Pharma Company Pipelines

Blog at WordPress.com. Theme: Digg 3 Column by WP Designer